Skip to main content
. 2015 Feb 9;125(3):1228–1242. doi: 10.1172/JCI77656

Figure 6. Ep3 deficiency suppresses TGF-β1 signaling pathway in hypoxia-treated PASMCs and PAs.

Figure 6

(A) Content of active TGF-β1 and total TGF-β1 in Ep3–/– and WT PASMC medium after normoxia or hypoxia treatment. (B) Western blot analysis of phosphorylated (p-) SMAD2/3 in Ep3–/– and WT PASMCs after normoxia or hypoxia treatment. (C and D) Quantification of SMAD2 and SMAD3 phosphorylation (n = 6). *P < 0.05 versus WT and #P < 0.05 versus normoxia by 2-way ANOVA with Bonferroni’s post-hoc analysis. (E) Immunofluorescence staining of p-SMAD2 (red) and α-SMA (green) of lung sections from normoxia- or hypoxia-treated Ep3–/– and WT mice. Scale bar: 20 μm.